HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supreme Court Ruling In Wyeth Case May Make FDA More Cautious

This article was originally published in The Tan Sheet

Executive Summary

How the U.S. Supreme Court rules in Wyeth v. Levine could limit the number of product liability suits brought against drug companies

You may also be interested in...



High Court’s Wyeth v. Levine Ruling Returns Pre-Emption Status Quo

The Supreme Court's ruling in Wyeth v. Levine dashes pharmaceutical industry hopes for broad protection from state product liability lawsuits, but is not expected to trigger a sea-change in current industry operations

Cigarette pre-emption claims up in smoke

The Supreme Court rules 5-4 that smokers can sue tobacco companies alleging advertising for "light" cigarettes was deceptive, rejecting Philip Morris' argument that state law claims are pre-empted by the Federal Cigarette Labeling and Advertising Act. The court says there is no conflict between state law and federal law, which neither expressly nor implicitly pre-empts fraud claims. The decision does not reveal how the court will rule in Wyeth v. Levine, concerning the drug industry's defense that FDA labeling regulations pre-empt state tort claims (1"The Tan Sheet" Nov. 10, 2008, p. 20). In a sign the cases are different, the U.S. Solicitor General submitted a brief opposing Philip Morris' claim, but argues for pre-emption in Wyeth v. Levine

Drug Industry Braces For Supreme Court Ruling In Wyeth Pre-emption Case

This week everyone's attention is riveted on the presidential election. But for the pharmaceutical industry there is another issue just as compelling. On Nov. 3, the U.S. Supreme Court will hear oral arguments in the case that will decide the future of product liability litigation

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS137720

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel